CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018

Neuro-Oncology - Tập 23 Số Supplement_3 - Trang iii1-iii105 - 2021
Quinn T. Ostrom1,2,3,4, Gino Cioffi1,5, Kristin Waite1,5, Carol Kruchko1, Jill S. Barnholtz‐Sloan6,1,5
1Central Brain Tumor Registry of the United States, Hinsdale, Illinois, USA
2Department of Neurosurgery, Duke University School of Medicine, Durham, NC, USA
3Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA
4The Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine, Durham, NC, USA
5Trans Divisional Research Program (TDRP), Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute, Bethesda, MD, USA
6Center for Biomedical Informatics & Information Technology (CBIIT), National Cancer Institute, Bethesda, MD, USA

Tóm tắt

Abstract The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control and Prevention (CDC) and National Cancer Institute (NCI), is the largest population-based cancer registry focused exclusively on primary brain and other central nervous system (CNS) tumors in the United States (US) and represents the entire US population. This report contains the most up-to-date population-based data on primary brain tumors available and supersedes all previous reports in terms of completeness and accuracy and is the first CBTRUS Report to provide the distribution of molecular markers for selected brain and CNS tumor histologies. All rates are age-adjusted using the 2000 US standard population and presented per 100,000 population. The average annual age-adjusted incidence rate (AAAIR) of all malignant and non-malignant brain and other CNS tumors was 24.25 (Malignant AAAIR=7.06, Non-malignant AAAIR=17.18). This overall rate was higher in females compared to males (26.95 versus 21.35) and non-Hispanics compared to Hispanics (24.68 versus 22.12). The most commonly occurring malignant brain and other CNS tumor was glioblastoma (14.3% of all tumors and 49.1% of malignant tumors), and the most common non-malignant tumor was meningioma (39.0% of all tumors and 54.5% of non-malignant tumors). Glioblastoma was more common in males, and meningioma was more common in females. In children and adolescents (age 0–19 years), the incidence rate of all primary brain and other CNS tumors was 6.21. An estimated 88,190 new cases of malignant and non-malignant brain and other CNS tumors are expected to be diagnosed in the US population in 2021 (25,690 malignant and 62,500 non-malignant). There were 83,029 deaths attributed to malignant brain and other CNS tumors between 2014 and 2018. This represents an average annual mortality rate of 4.43 per 100,000 and an average of 16,606 deaths per year. The five-year relative survival rate following diagnosis of a malignant brain and other CNS tumor was 35.6%, for a non-malignant brain and other CNS tumors the five-year relative survival rate was 91.8%.

Từ khóa


Tài liệu tham khảo

Kruchko, 2018, The CBTRUS story: providing accurate population-based statistics on brain and other central nervous system tumors for everyone, Neuro Oncol., 20, 295, 10.1093/neuonc/noy006

Louis, 2016, WHO Classification of Tumours of the Central Nervous System.

Centers for Disease Control and Prevention (CDC), 1999

Wiśniewski, 2009, Universal sample preparation method for proteome analysis, Nat Methods., 6, 359, 10.1038/nmeth.1322

2002

National Cancer Institute

Walker, 2019, Malignant primary brain and other central nervous system tumors diagnosed in Canada from 2009 to 2013, Neuro Oncol, 21, 360, 10.1093/neuonc/noy195

Wöhrer, 2009, The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry, J Neurooncol., 95, 401, 10.1007/s11060-009-9938-9

Asklund, 2015, Brain tumors in Sweden: data from a population-based registry 1999–2012, Acta Oncol, 54, 377, 10.3109/0284186X.2014.975369

Centers for Disease Control and Prevention National Center for Health Statistics, 2021, National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database: U.S. Cancer Statistics Incidence Analytic Database – 2001–2018

Fritz, 2000, International Classification of Diseases for Oncology

McCarthy, 2002, Consensus Conference on Brain Tumor Definition for registration. November 10, 2000, Neuro Oncol, 134

Surveillance Epidemiology aERSP, 2017, Third Edition

2017, International Incidence of Childhood Cancer, Volume III

Steliarova-Foucher, 2005, International Classification of Childhood Cancer, third edition, Cancer., 103, 1457, 10.1002/cncr.20910

Swerdlow, 2007, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues

Kleihues, 2000, Tumours of the nervous system: World Health Organization classification of tumours

Louis, 2007, WHO Classification of Tumours of the Central Nervous System

American Joint Committee on Cancer, 2020

Ostrom, 2016, Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004–2012, varying), J Neurooncol, 130, 31, 10.1007/s11060-016-2217-7

Lym, 2015, Completeness and concordancy of WHO grade assignment for brain and central nervous system tumors in the United States, 2004–2011, Journal of neuro-oncology, 10.1007/s11060-015-1775-4

Surveillance Research Program - National Cancer Institute, 2019

Ostrom, 2014, CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007–2011, Neuro Oncol, 16, iv1, 10.1093/neuonc/nou223

Ferlay, 2019, Histological groups, Cancer Incidence in Five Continents Volume XI

Surveillance Epidemiology and End Results (SEER) Program, 2019

Ostrom, 2020, Pilocytic astrocytomas: where do they belong in cancer reporting?, Neuro Oncol., 22, 298

Surveillance Epidemiology and End Results (SEER) Program, 2020

2008

Bray, 2017, Data Comparability and Quality, Cancer Incidence in Five Continents, Vol. XI (electronic version)

R Core Team, 2021

Surveillance Epidemiology and End Results (SEER) Program, 2020

Luo, 2012

Gohel, 2020

Gohel, 2020

Hočevar, 2016, Computation of Graphlet Orbits for Nodes and Edges in Sparse Graphs, 2016, 71, 24

Wickham, 2019, Welcome to the Tidyverse, Journal of Open Source Software, 4, 1686, 10.21105/joss.01686

Sievert, 2020

Xie, 2020

Walker, 2020

Kassambara, 2020

Pebesma, 2018, Simple Features for R: Standardized Support for Spatial Vector Data, The R Journal, 10, 439, 10.32614/RJ-2018-009

NAACCR Race and Ethnicity Work Group, 2012

Surveillance Epidemiology and End Results (SEER) Program, 2020

Tiwari, 2006, Efficient interval estimation for age-adjusted cancer rates, Statistical methods in medical research, 547

Fay, 2006, Estimating average annual percent change for disease rates without assuming constant change, Biometrics., 62, 847, 10.1111/j.1541-0420.2006.00528.x

2021

Kim, 2000, Permutation tests for joinpoint regression with applications to cancer rates, Stat Med., 19, 335, 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z

Zhu, 2012, Predicting US- and state-level cancer counts for the current calendar year: Part II: evaluation of spatiotemporal projection methods for incidence, Cancer., 118, 1100, 10.1002/cncr.27405

Surveillance Epidemiology and End Results (SEER) Program, 2020, SEER*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1969–2018) &lt;Katrina/Rita Population Adjustment&gt;, National Cancer Institute, DCCPS, Surveillance Research Program, released December 2020

Edwards, 2014, Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer, Cancer, 120, 1290, 10.1002/cncr.28509

Zullig, 2012, Cancer incidence among patients of the U.S. Veterans Affairs Health Care System, Mil Med., 177, 693, 10.7205/MILMED-D-11-00434

Clegg, 2002, Impact of reporting delay and reporting error on cancer incidence rates and trends, Journal of the National Cancer Institute, 1537

Midthune, 2005, Modeling Reporting Delays and Reporting Corrections in Cancer Registry Data, Journal of the American Statistical Association, 100, 61, 10.1198/016214504000001899

Surveillance Epidemiology and End Results (SEER) Program, 2020

Li, 2016, Are Benign and Borderline Brain Tumors Underreported?, J Registry Manag., 43, 187

Anderson, Report of the Second Workshop on Age Adjustment, Vital and health statistics. Ser. 4, Documents and committee reports, 1998, I

Anderson, 1998, Age standardization of death rates: implementation of the year 2000 standard, National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System, 47, 1

L. D, 2018

Johnson, 2007, The 2007 Multiple Primary and Histology Coding Rules

Ostrom, 2016, Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004–2012, varying), Journal of neuro-oncology, 130, 31, 10.1007/s11060-016-2217-7

Reifenberger, 2017, Advances in the molecular genetics of gliomas - implications for classification and therapy, Nat Rev Clin Oncol., 14, 434, 10.1038/nrclinonc.2016.204

Cairncross, 1998, Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas, J Natl Cancer Inst., 90, 1473, 10.1093/jnci/90.19.1473

Cairncross, 2013, Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402, J Clin Oncol., 31, 337, 10.1200/JCO.2012.43.2674

Vogelbaum, 2015, Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131, J Neurooncol., 124, 413, 10.1007/s11060-015-1845-7

van den Bent, 2013, Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951, J Clin Oncol., 31, 344, 10.1200/JCO.2012.43.2229

Eckel-Passow, 2015, Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors, N Engl J Med., 372, 2499, 10.1056/NEJMoa1407279

Yan, 2009, IDH1 and IDH2 mutations in gliomas, N Engl J Med., 360, 765, 10.1056/NEJMoa0808710

The Cancer Genome Atlas Research Network, 2015, Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas, New England Journal of Medicine, 372, 2481, 10.1056/NEJMoa1402121

Qi, 2014, Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms, Oncol Lett., 7, 1895, 10.3892/ol.2014.2013

Paldor, 2016, Frontal glioblastoma multiforme may be biologically distinct from non-frontal and multilobar tumors, J Clin Neurosci., 34, 128, 10.1016/j.jocn.2016.05.017

Ceccarelli, 2016, Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma, Cell., 164, 550, 10.1016/j.cell.2015.12.028

Hegi, 2005, MGMT gene silencing and benefit from temozolomide in glioblastoma, N Engl J Med., 352, 997, 10.1056/NEJMoa043331

Hegi, 2008, Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity, J Clin Oncol., 26, 4189, 10.1200/JCO.2007.11.5964

Stupp, 2007, Chemoradiotherapy in malignant glioma: standard of care and future directions, J Clin Oncol., 25, 4127, 10.1200/JCO.2007.11.8554

Noushmehr, 2010, Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma, Cancer Cell., 17, 510, 10.1016/j.ccr.2010.03.017

van den Bent, 2013, MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951, Clin Cancer Res., 19, 5513, 10.1158/1078-0432.CCR-13-1157

Jones, 2014, Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma, Nature reviews. Cancer, 14, 10.1038/nrc3811

Wu, 2014, The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma, Nat Genet., 46, 444, 10.1038/ng.2938

Mackay, 2017, Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma, Cancer Cell, 32, 520, 10.1016/j.ccell.2017.08.017

Hoffman, 2016, Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics, Acta Neuropathol Commun., 4, 1, 10.1186/s40478-015-0269-0

Grill, 2012, Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma, Pediatr Blood Cancer., 58, 489, 10.1002/pbc.24060

Lapin, 2017, Genomic Insights into Diffuse Intrinsic Pontine Glioma, Front Oncol., 7, 57, 10.3389/fonc.2017.00057

Kool, 2012, Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas, Acta Neuropathol., 123, 473, 10.1007/s00401-012-0958-8

Northcott, 2012, Molecular subgroups of medulloblastoma, Expert Rev Neurother., 12, 871, 10.1586/ern.12.66

Northcott, 2012, Medulloblastomics: the end of the beginning, Nat Rev Cancer., 12, 818, 10.1038/nrc3410

Northcott, 2017, The whole-genome landscape of medulloblastoma subtypes, Nature., 547, 311, 10.1038/nature22973

Ostrom, 2018, Females have the survival advantage in glioblastoma, Neuro Oncol., 10.1093/neuonc/noy002

Ostrom, 2018, Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014, JAMA oncology, 4, 1254, 10.1001/jamaoncol.2018.1789

Gittleman, 2019, Sex is an important prognostic factor for glioblastoma but not for nonglioblastoma, Neurooncol Pract.

Siegel, 2019, Cancer statistics, 2019, CA Cancer J Clin., 69, 7, 10.3322/caac.21551

Weir, 2014, Evaluation of North American Association of Central Cancer Registries’ (NAACCR) data for use in population-based cancer survival studies, J Natl Cancer Inst Monogr., 2014, 198, 10.1093/jncimonographs/lgu018

Wilson, 2014, Coding completeness and quality of relative survival-related variables in the National Program of Cancer Registries Cancer Surveillance System, 1995–2008, J Registry Manag., 41, 65

Kleihues, 1993, The new WHO classification of brain tumours, Brain Pathol., 3, 255, 10.1111/j.1750-3639.1993.tb00752.x

Louis, 2021, The 2021 WHO Classification of Tumors of the Central Nervous System: a summary, Neuro Oncol., 10.1093/neuonc/noab106

van den Bent, 2010, Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective, Acta Neuropathol., 120, 297, 10.1007/s00401-010-0725-7

Aldape, 2000, Discrepancies in diagnoses of neuroepithelial neoplasms: the San Francisco Bay Area Adult Glioma Study, Cancer., 88, 2342, 10.1002/(SICI)1097-0142(20000515)88:10<2342::AID-CNCR19>3.0.CO;2-X

Kruchko, 2019, Cancer collection efforts in the United States provide clinically relevant data on all primary brain and other CNS tumors, Neurooncol Pract., 6, 330

Thông tin
Thông tin xuất bản

Neuro-Oncology

Tập 23 Số Supplement_3

iii1-iii105

Thông tin tác giả